These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35177374)

  • 1. Evaluation of patient satisfaction and perceptions of a long-acting injectable antipsychotic medication administration service in a community-based pharmacy during the COVID-19 pandemic.
    Mascari LN; Gatewood SS; Kaefer TN; Nadpara P; Goode JR; Crouse E
    J Am Pharm Assoc (2003); 2022; 62(4S):S29-S34. PubMed ID: 35177374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site.
    Forster SE; Gancz NN; Gaither ML; Haas GL; Starver KD; Steinhauer SR
    J Psychiatr Pract; 2022 Nov; 28(6):497-504. PubMed ID: 36355590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy.
    Mooney EV; Hamper JG; Willis RT; Farinha TL; Ricchetti CA
    J Am Pharm Assoc (2003); 2018; 58(4S):S24-S29.e2. PubMed ID: 30006184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.
    McKee KA; Crocker CE; Tibbo PG
    BMC Psychiatry; 2021 Dec; 21(1):633. PubMed ID: 34930204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining long-acting injectable antipsychotic (depot) medication in the elderly: a five-year retrospective cross-sectional study evaluating depot use in an Australian psychogeriatric service.
    Doolabh U; Yeap S
    Australas Psychiatry; 2022 Feb; 30(1):31-36. PubMed ID: 34247547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.
    Sun Y; Tong J; Feng Y; Fang H; Jiang T; Zhao L; Wang Q; Yang Y
    Front Public Health; 2022; 10():951544. PubMed ID: 36299738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Barlati S; Nibbio G; Bianchi F; Gigli EBL; Calzavara-Pinton I; Cerati C; Fiori J; Lisoni J; Deste G; Vita A
    Psychiatry Res; 2022 Nov; 317():114878. PubMed ID: 36206591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.
    Correll CU; Chepke C; Gionfriddo P; Parks J; Foxworth P; Basu A; Brister TS; Brown D; Clarke C; Hassoun Y
    BMC Psychiatry; 2022 Jan; 22(1):32. PubMed ID: 35012512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis.
    Okoli CTC; Kappi A; Wang T; Makowski A; Cooley AT
    Int J Ment Health Nurs; 2022 Jun; 31(3):469-535. PubMed ID: 34931437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.
    Geerts P; Martinez G; Schreiner A
    BMC Psychiatry; 2013 Feb; 13():58. PubMed ID: 23414331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.